Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance

被引:0
作者
S. A. Foster
K. A. Foley
E. S. Meadows
J. A. Johnston
S. S. Wang
G. M. Pohl
S. R. Long
机构
[1] Lilly Corporate Center,Eli Lilly and Company
[2] Thomas Jefferson University,Lilly USA
[3] Thomson Reuters,undefined
[4] LLC,undefined
来源
Osteoporosis International | 2011年 / 22卷
关键词
Adherence; Osteoporosis; Persistence; Teriparatide;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:551 / 557
页数:6
相关论文
共 88 条
  • [1] Neer RM(2001)Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-1441
  • [2] Arnaud CD(2007)Non-compliance: the Achilles’ heel of anti-fracture efficacy Osteoporos Int 18 711-719
  • [3] Zanchetta JR(2004)The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003-1008
  • [4] Prince R(2006)Determinants of adherence to osteoporosis treatments in clinical practice Osteoporos Intl 17 914-921
  • [5] Gaich GA(2006)Compliance with drug therapy for postmenopausal osteoporosis Osteoporos Int 17 1645-1652
  • [6] Reginster JY(2006)Persistence with teriparatide in patients with osteoporosis: the UK experience Osteoporos Int 17 1626-1629
  • [7] Hodsman AB(2009)Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience Osteoporos Int 20 625-630
  • [8] Eriksen EF(2008)Characteristics of patients initiating teriparatide for the treatment of osteoporosis Osteoporos Int 19 373-377
  • [9] Ish-Shalom S(2007)Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493-1501
  • [10] Genant HK(2005)Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453-1460